Cargando…

Juvenile idiopathic arthritis patients with positive family history of autoimmune thyroid disease might benefit from serological screening: analysis of the international Pharmachild registry

BACKGROUND: Little is known about the association between juvenile idiopathic arthritis (JIA) and autoimmune thyroid disease (AITD) and therefore there are no indications for AITD screening in this population, which is possible using standard blood tests. The objective of this study is to determine...

Descripción completa

Detalles Bibliográficos
Autores principales:	van Straalen, Joeri W., Baas, Laurie, Giancane, Gabriella, Grebenkina, Lyudmila, Brunner, Jurgen, Vega-Cornejo, Gabriel, Chasnyk, Vyacheslav G., Harel, Liora, Appenzeller, Simone, Gervais, Elisabeth, de Roock, Sytze, Wulffraat, Nico M., Ruperto, Nicolino, Swart, Joost F.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9945712/ https://www.ncbi.nlm.nih.gov/pubmed/36810111 http://dx.doi.org/10.1186/s12969-023-00802-1

Ejemplares similares

Prevalence of familial autoimmune diseases in juvenile idiopathic arthritis: results from the international Pharmachild registry
por: van Straalen, Joeri W., et al.
Publicado: (2022)

Pharmacovigilance in juvenile idiopathic arthritis patients (Pharmachild) treated with biologic agents and/or methotrexate. Consolidated baseline characteristics from Pharmachild and other national registries
por: Swart, Joost, et al.
Publicado: (2014)

Opportunistic infections in immunosuppressed patients with juvenile idiopathic arthritis: analysis by the Pharmachild Safety Adjudication Committee
por: Giancane, Gabriella, et al.
Publicado: (2020)

Real-world comparison of the effects of etanercept and adalimumab on well-being in non-systemic juvenile idiopathic arthritis: a propensity score matched cohort study
por: van Straalen, Joeri W., et al.
Publicado: (2022)

Methotrexate therapy associated with a reduced rate of new-onset uveitis in patients with biological-naïve juvenile idiopathic arthritis
por: van Straalen, Joeri W, et al.
Publicado: (2023)

A clinical prediction model for estimating the risk of developing uveitis in patients with juvenile idiopathic arthritis
por: van Straalen, Joeri W, et al.
Publicado: (2020)

Burden of comorbid conditions in children and young people with juvenile idiopathic arthritis: a collaborative analysis of 3 JIA registries
por: Kearsley-Fleet, Lianne, et al.
Publicado: (2021)

Pharmacovigilance in juvenile idiopathic arthritis patients treated with biologic or synthetic drugs: combined data of more than 15,000 patients from Pharmachild and national registries
por: Swart, Joost, et al.
Publicado: (2018)

What are the immunological consequences of long-term use of biological therapies for juvenile idiopathic arthritis?
por: Swart, Joost F, et al.
Publicado: (2013)

Increased incidence of inflammatory bowel disease on etanercept in juvenile idiopathic arthritis regardless of concomitant methotrexate use
por: van Straalen, Joeri W, et al.
Publicado: (2021)

Clinical Juvenile Arthritis Disease Activity Score proves to be a useful tool in treat-to-target therapy in juvenile idiopathic arthritis
por: Swart, Joost F, et al.
Publicado: (2018)

Development and External Validation of a Model Predicting New‐Onset Chronic Uveitis at Different Disease Durations in Juvenile Idiopathic Arthritis
por: van Straalen, Joeri W., et al.
Publicado: (2022)

PReS-FINAL-2147: Immunological consequences of biologicals in juvenile idiopathic arthritis
por: Swart, JF, et al.
Publicado: (2013)

Bone-marrow derived mesenchymal stromal cells infusion in therapy refractory juvenile idiopathic arthritis patients
por: Swart, Joost F, et al.
Publicado: (2019)

Tapering Canakinumab Monotherapy in Patients With Systemic Juvenile Idiopathic Arthritis in Clinical Remission: Results From a Phase IIIb/IV Open‐Label, Randomized Study
por: Quartier, Pierre, et al.
Publicado: (2020)

The Hebrew version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR)
por: Uziel, Yosef, et al.
Publicado: (2018)

Monitoring patients with juvenile idiopathic arthritis using health-related quality of life
por: Doeleman, Martijn J. H., et al.
Publicado: (2021)

PReS-FINAL-2107: In vitro investigation into mesenchymal stromal cells as a potential therapeutic in juvenile arthritis
por: Wienke, J, et al.
Publicado: (2013)

Mesenchymal stromal cells suppress synovial fluid-derived t cells from juvenile idiopathic arthritis patients in vitro
por: Wienke, J, et al.
Publicado: (2014)

High Treg development in the first year of life gives insight into immune regulation
por: De Roock, Sytze, et al.
Publicado: (2014)

Mesenchymal stem cells and JIA
por: Swart, JF, et al.
Publicado: (2011)

The Dutch version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR)
por: Wulffraat, Nico, et al.
Publicado: (2018)

Pharmacological treatment patterns in patients with juvenile idiopathic arthritis in the Netherlands: a real-world data analysis
por: Kip, Michelle M A, et al.
Publicado: (2022)

Towards European harmonisation of healthcare for patients with rare immune disorders: outcome from the ERN RITA registries survey
por: Papa, Riccardo, et al.
Publicado: (2020)

The protective effect of COVID-19 vaccines on developing multisystem inflammatory syndrome in children (MIS-C): a systematic literature review and meta-analysis
por: Hamad Saied, Mohamad, et al.
Publicado: (2023)

Current evidence for the medical treatments of systemic juvenile idiopathic arthritis
por: Ruperto, Nicolino
Publicado: (2014)

Costs of Hospital‐Associated Care for Patients With Juvenile Idiopathic Arthritis in the Dutch Health Care System
por: Kip, Michelle M. A., et al.
Publicado: (2022)

The Flemish version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR)
por: Dehoorne, Joke, et al.
Publicado: (2018)

Maintenance of antibody response to diphtheria/tetanus vaccine in patients aged 2–5 years with polyarticular-course juvenile idiopathic arthritis receiving subcutaneous abatacept
por: Brunner, Hermine I., et al.
Publicado: (2020)

Tocilizumab may slow radiographic progression in patients with systemic or polyarticular-course juvenile idiopathic arthritis: post hoc radiographic analysis from two randomized controlled trials
por: Malattia, Clara, et al.
Publicado: (2020)

Current Medical Treatments for Juvenile Idiopathic Arthritis
por: Ruperto, Nicolino, et al.
Publicado: (2011)

The human microbiome and juvenile idiopathic arthritis
por: Verwoerd, Anouk, et al.
Publicado: (2016)

Etanercept treatment for extended oligoarticular juvenile idiopathic arthritis, enthesitis-related arthritis, or psoriatic arthritis: 6-year efficacy and safety data from an open-label trial
por: Foeldvari, Ivan, et al.
Publicado: (2019)

IL-18 production upon s100 stimulation is reduced in active sJIA patients compared to sJIA patients in remission and healthy controls
por: Haar, Nienke Ter, et al.
Publicado: (2014)

Efficacy and safety of open-label etanercept on extended oligoarticular juvenile idiopathic arthritis, enthesitis-related arthritis and psoriatic arthritis: part 1 (week 12) of the CLIPPER study
por: Horneff, Gerd, et al.
Publicado: (2014)

Early changes in gene expression and inflammatory proteins in systemic juvenile idiopathic arthritis patients on canakinumab therapy
por: Brachat, Arndt H., et al.
Publicado: (2017)

PD-1/PD-L1 signaling in JIA synovial regulatory T cell function
por: de Roock, Sytze, et al.
Publicado: (2011)

Share – Workpackage 4: addressing the need for health care for paediatric rheumatic diseases throughout europe
por: Dolezalova, Pavla, et al.
Publicado: (2014)

Treatment to Target Using Recombinant Interleukin‐1 Receptor Antagonist as First‐Line Monotherapy in New‐Onset Systemic Juvenile Idiopathic Arthritis: Results From a Five‐Year Follow‐Up Study
por: ter Haar, Nienke M., et al.
Publicado: (2019)

Secukinumab in enthesitis-related arthritis and juvenile psoriatic arthritis: a randomised, double-blind, placebo-controlled, treatment withdrawal, phase 3 trial
por: Brunner, Hermine I, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_vt6pq9i2fr8gvkdopok3a8mm9d